Milestone Pharmaceuticals Inc (MIST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has a cash flow conversion efficiency ratio of -0.479x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.82 Million) by net assets ($20.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Milestone Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Milestone Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MIST cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Milestone Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ANDRADA MINING LTD.
F:9IA
|
N/A |
|
Klingelnberg AG
SW:KLIN
|
0.142x |
|
Syntec Construction Public Company Limited
BK:SYNTEC
|
-0.046x |
|
Yunsa Yunlu Sanayi ve Ticaret AS
IS:YUNSA
|
0.030x |
|
Fortune Mate Indonesia Tbk
JK:FMII
|
-0.005x |
|
Bioneer Corporation
KQ:064550
|
0.004x |
|
S&D Co. Ltd.
KQ:260970
|
0.014x |
|
Silver One Resources Inc
V:SVE
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Milestone Pharmaceuticals Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Milestone Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.15 Million | $-28.85 Million | -2.194x | +20.73% |
| 2023-12-31 | $16.77 Million | $-46.42 Million | -2.768x | -250.03% |
| 2022-12-31 | $66.35 Million | $-52.47 Million | -0.791x | -168.02% |
| 2021-12-31 | $112.60 Million | $-33.22 Million | -0.295x | +16.76% |
| 2020-12-31 | $143.12 Million | $-50.73 Million | -0.354x | +20.36% |
| 2019-12-31 | $114.92 Million | $-51.15 Million | -0.445x | -216.77% |
| 2018-12-31 | $-55.21 Million | $-21.05 Million | 0.381x | +56.79% |
| 2017-12-31 | $-33.12 Million | $-8.05 Million | 0.243x | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more